Placebo News and Research

RSS

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Researchers from Brigham and Women's Hospital and the University of Murcia, Spain, have shed new light on why people who carry a common genetic mutation may be more at risk for developing type 2 diabetes. By carefully studying healthy subjects, researchers were able to chart the effect of melatonin supplements on blood sugar control.

7 Oct 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

6 Oct 2015

First patients screened in Axovant's phase 3 study of RVT-101

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.

6 Oct 2015

Nivolumab, ipilimumab duo effective in poor prognosis advanced melanoma patients

Subgroups of advanced melanoma patients with a poor prognosis derive a progression-free survival benefit from the combination of nivolumab and ipilimumab, according to research presented at the European Cancer Congress in Vienna, Austria.

5 Oct 2015

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show.

2 Oct 2015

6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

The 6-minute walk distance of patients with systemic sclerosis-associated pulmonary arterial hypertension is not a suitable marker for tracking treatment-related haemodynamic changes, say researchers.

2 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Understanding neurobiological mechanisms of empathy

In a study with more than 100 participants, Claus Lamm and his interdisciplinary team used an innovative experimental trick, the so-called placebo analgesia effect, to close an explanatory gap in the understanding of the neurobiological mechanisms of empathy.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015

29 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

Two-drug combination relieves depression in older adults

More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.

28 Sep 2015

Study may lead to new insights on use of aspirin in GI cancer

Aspirin improves survival in patients with tumours situated throughout the gastrointestinal (GI) tract, results from a large study in The Netherlands show. This is the first time that survival data from patients with tumours in different GI locations have been analysed at the same time; previously, only one type of cancer, usually colorectal, was studied.

28 Sep 2015

SLU participates in Phase III clinical trial to treat early-onset preeclampsia

Saint Louis University is participating in a Phase III clinical trial for a drug to treat early-onset preeclampsia in pregnant women that could increase the length of pregnancy, resulting in improved fetal outcomes and reduced infant mortality.

26 Sep 2015

University of Oslo researchers examine treatment methods for tennis elbow

The two most common treatments for tennis elbow are physiotherapy and cortisone injections. It is unclear which of these gives the best result, and diagnosis can be problematic for general practitioners. Now researchers at the University of Oslo have taken a closer look at the treatment methods.

25 Sep 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie, a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients with inadequate response to either methotrexate or TNF inhibitors.

25 Sep 2015

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Rhythm announced today the award of a $1 million research grant from the FDA Office of Orphan Products Development to its subsidiary, Rhythm Metabolic, Inc., to support the ongoing Phase 2 clinical trial of setmelanotide, the company's novel peptide MC4 agonist, for the treatment of obesity and hyperphagia in Prader-Willi syndrome (PWS).

24 Sep 2015

Placebo News and Research

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

First patients screened in Axovant's phase 3 study of RVT-101

Nivolumab, ipilimumab duo effective in poor prognosis advanced melanoma patients

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Understanding neurobiological mechanisms of empathy

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Two-drug combination relieves depression in older adults

Study may lead to new insights on use of aspirin in GI cancer

SLU participates in Phase III clinical trial to treat early-onset preeclampsia

University of Oslo researchers examine treatment methods for tennis elbow

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

Rhythm Metabolic awarded FDA grant to advance ongoing setmelanotide clinical trial in Prader-Willi syndrome

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News